LIOTHYRONINE SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Liothyronine Sodium, and when can generic versions of Liothyronine Sodium launch?
Liothyronine Sodium is a drug marketed by Xgen Pharms, Biocon Pharma, Dr Reddys Labs Sa, Norvium Bioscience, Sigmapharm Labs Llc, Sun Pharm, Teva Pharms Usa, Watson Labs, and Zydus Lifesciences. and is included in ten NDAs.
The generic ingredient in LIOTHYRONINE SODIUM is liothyronine sodium. There are four drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the liothyronine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Liothyronine Sodium
A generic version of LIOTHYRONINE SODIUM was approved as liothyronine sodium by XGEN PHARMS on August 17th, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LIOTHYRONINE SODIUM?
- What are the global sales for LIOTHYRONINE SODIUM?
- What is Average Wholesale Price for LIOTHYRONINE SODIUM?
Summary for LIOTHYRONINE SODIUM
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 10 |
| Finished Product Suppliers / Packagers: | 19 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Clinical Trials: | 15 |
| Patent Applications: | 1,189 |
| What excipients (inactive ingredients) are in LIOTHYRONINE SODIUM? | LIOTHYRONINE SODIUM excipients list |
| DailyMed Link: | LIOTHYRONINE SODIUM at DailyMed |
Recent Clinical Trials for LIOTHYRONINE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Minnesota | Phase 1/Phase 2 |
| University of Minnesota - Clinical and Translational Science Institute | Phase 1/Phase 2 |
| Aultman Health Foundation | Phase 2 |
Pharmacology for LIOTHYRONINE SODIUM
| Drug Class | l-Triiodothyronine |
Anatomical Therapeutic Chemical (ATC) Classes for LIOTHYRONINE SODIUM
US Patents and Regulatory Information for LIOTHYRONINE SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xgen Pharms | LIOTHYRONINE SODIUM | liothyronine sodium | INJECTABLE;INJECTION | 076923-001 | Aug 17, 2005 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharms Usa | LIOTHYRONINE SODIUM | liothyronine sodium | TABLET;ORAL | 211510-002 | Oct 26, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Lifesciences | LIOTHYRONINE SODIUM | liothyronine sodium | TABLET;ORAL | 214803-003 | Jan 22, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
